This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk (NVO) Announces Results in Diabetes Studies
by Zacks Equity Research
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
by Zacks Equity Research
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
LLY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk's Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
Top Research Reports for Walmart, AT&T & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AT&T (T) and Novo Nordisk (NVO).
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Novo Nordisk Obtains Licence for Sickle Cell Disease Program
by Zacks Equity Research
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Novo Nordisk Poised on Strong Pipeline Amid Competition
by Zacks Equity Research
Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
by Zacks Equity Research
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP
by Zacks Equity Research
CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm
by Zacks Equity Research
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Eurozone Beats United States Again: 5 Hot Stock Picks
by Zacks Equity Research
5 Europe-based stocks to buy as the region scores decade-high growth rate in 2017.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat
by Zacks Equity Research
Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.
Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.
Company News For Jan 30, 2018
by Zacks Equity Research
Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO
Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B
by Zacks Equity Research
Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.
Why Novo Nordisk (NVO) Might Surprise This Earnings Season
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call
by Arpita Dutt
With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.
AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.